Business

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

DALLAS, April 24, 2026--Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

articleLantern Pharma Inc.April 24, 20268/company/lantern-pharma-inc/news/lantern-pharma-to-debut-public-demonstration-of-withzetaai-a-platform-to-conquer-rare-cancers-on-april-30-following-aacr-2026-scientific-debut
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

About this update from Lantern Pharma Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/ba57d0aebcfe5f6ce40ab10171fd0630"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p96go3HBmbp00CrZkFyx.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/ba57d0aebcfe5f6ce40ab10171fd0630","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 — Open to Investors, Researchers, and the Global Biomedical Community","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Registration Link & Details Can be Accessed Below","length":53,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":231,"olType":false},{"type":"text","content":"DALLAS, April 24, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic AI co-scientist platform, to be held on Thursday, April 30, 2026. The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the first time the platform will be demonstrated live and without restriction to a global public audience of investors, researchers, and industry participants.","length":686,"tagName":"p"},{"type":"text","content":"President and Chief Executive Officer Panna Sharma will lead the demonstration in real time — live, interactive, and unrehearsed — showing how withZeta.ai operates as a genuine AI co-scientist at the frontier of oncology drug discovery. Two identical sessions will be held to accommodate global time zones:","length":306,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Morning Session: 8:30 AM ET — Register Here","length":43,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Afternoon Session: 4:30 PM ET — Register Here","length":45,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":88,"...

More updates from Lantern Pharma Inc.

drug discoveryNasdaq MarketSiteAACRLanternLantern Pharmaprecision oncologydrug developmentAfternoon SessionLantern Pharma Inc.Morning SessionResearchers